Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Instagram Outage Disrupts Thousands of U.S. Users 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
SAN FRANCISCO, Dec. 21, 2017 -- David Kideckel, an analyst with Beacon Securities Ltd., relayed news from this firm's recent annual meeting, including a private placement with a large pharma and an update on the Phase 3 trial of its lead therapy.
Included in this article is: Resverlogix Corp. (RVX:TSX)
Kideckel reported in a Dec. 13 research note that at Resverlogix Corp.'s general meeting in Calgary, Alberta on Dec. 12, the company announced that on Dec. 4, it closed a CA$87 million (CA$87M) private placement with Shenzhen Hepalink, "the world's largest heparin producer," wrote Kideckel, who defined the event as a "major endorsement from [a] world-leading pharma company." Subsequently, Resverlogix fully repaid its outstanding CA$68.8M loan.
In clinical news, Kideckel said, management indicated the company has achieved enrollment of about 2,000 patients for the Phase 3 BETonMACE trial of its lead drug candidate apabetalone in high-risk cardiovascular disease.
Also regarding apabetalone, Resverlogix highlighted a "new, independent publication in Nature Scientific Reports" that suggested it may be beneficial to HIV therapies, Kideckel reported.
In 2018, Resverlogix plans to pursue the complement-mediated diseases space, in which it has "made great progress," Kideckel wrote. He added that "this new research and development focus remains an impressive path for Resverlogix, with significant upside potential."
Continue reading this article: Biotech Receives 'Major Endorsement from World-Leading Pharma Company'
About Streetwise Reports – The Life Sciences Report
Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
DISCLOSURES:
The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Resverlogix Corp. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
Please see the end of the article for the complete disclosures: Biotech Receives 'Major Endorsement from World-Leading Pharma Company'
Contact Information: Carrie Beal Amaro Publisher [email protected]
